Black box warnings on fluoroquinolone

13 July 2008

The US Food and Drug Administration has asked manufacturers of fluoroquinolone antimicrobial drugs to place a boxed warning on their labeling advising of the increased risk of tendinitis and tendon rupture and provide a Medication Guide to patients about possible side effects.

Fluoroquinolones are used for the treatment or prevention of certain bacterial infections. Drugs in this class include Bayer's Cipro/Ciprobay (ciprofloxacin), which lost patent protection in 2006. The German drugmaker also makes another affected antibiotic, Avalox/Avelox (moxifloxacin). The agent is sold by local licensee Schering-Plough in the USA, where it earned $75.0 million in second-quarter 2008. The recently-launched fluoroquinolone Factive (gemifloxacin mesylate) was approved in May last year and is seen as a key revenue driver for USA-based Oscient.

The antibiotic Levaquin (levofloxacin) was one of the top seven best performing drugs for US health care major Johnson & Johnson last year. Other fluoroquinolones include Depomed's ProQuin XR, a once-daily, extended-release formulation of the off-patent antibiotic ciprofloxacin and Merck & Co's Noroxin/Chibroxin (norfloxacin), which lost patent protection in 2000.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight